"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","treatment_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","description.1","data_processing","data_processing.1","data_processing.2","data_processing.3","platform_id","contact_name","contact_email","contact_phone","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","condition:ch1"
"GSM1954293","TLDA-139","GSM1954293","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: healty","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 1","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","healty"
"GSM1954294","TLDA-140","GSM1954294","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: healty","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 2","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","healty"
"GSM1954295","TLDA-141","GSM1954295","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: healty","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 3","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","healty"
"GSM1954296","TLDA-143","GSM1954296","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: chronic myeloid leukemia","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 4","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","chronic myeloid leukemia"
"GSM1954297","TLDA-144","GSM1954297","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: chronic myeloid leukemia","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 5","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","chronic myeloid leukemia"
"GSM1954298","TLDA-145","GSM1954298","Public on Mar 31 2016","Nov 25 2015","Mar 31 2016","RNA","1","exosome","Homo sapiens","condition: chronic myeloid leukemia","Peripheral blood mononuclear cells (PBMCs) were harvested form 10ml of whole blood.","total RNA","Total RNA was isolated with the mirVana PARIS kit (Ambion, Austin, TX, USA).","TaqMan probe (FAM-MGB)","A fixed volume of 3 μl of RNA solution from 50 μl of the elute was used as input in each reverse transcription (RT) reaction. An RT reaction and pre-amplification step were set up according to manufacturers’ recommendations. miRNAs were reverse transcribed using the Megaplex Primer Pools (Human Pools A v2.1) from Applied Biosystems (Bedford, MA, USA). RT reaction products from the exosome sample were further amplified using the Megaplex PreAmp Primers (Primers A v2.1).","9606","n/a","n/a","test","SAMPLE 6","ath-miR-159 were used as a control. QRT-PCR was carried out on an Applied Biosystems 7900HT thermal cycler using the manufacturer’s recommended program.","All the raw data from each array was retrieved from the 7900HT and was run on Data Assist Software ver.3.1 (Applied Biosystems).","With the use of SDS2.2 software and Data Assist (Thermo Fisher Sciences), the expression of plasma miRNAs was calculated based on cycle threshold (Ct) values normalized by those of ath-miR-159, which was spiked in each plasma sample. Data analysis was done using GeneSiferⓇ software (Perkin Elmer, Waltham, MA, USA). The Benjamini-Hochberg algorithm was used for estimation of false discovery rates.","Fold Change worksheet reports test/control ratios.","GPL13987","Tomohiro,,Umezu","t_umezu@tokyo-med.ac.jp","+81-3-3342-6111","Department of Molecular Science","Tokyo Medical University","6-7-1 Nishi-shinjyuku","Shinjyuku","Tokyo","160-0023","Japan","NONE","384","chronic myeloid leukemia"
